These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases. Pérez-Llarena FJ, Cartelle M, Mallo S, Beceiro A, Pérez A, Villanueva R, Romero A, Bonnet R, Bou G. J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307 [Abstract] [Full Text] [Related]
3. Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9. Delmas J, Robin F, Carvalho F, Mongaret C, Bonnet R. Antimicrob Agents Chemother; 2006 Feb; 50(2):731-8. PubMed ID: 16436733 [Abstract] [Full Text] [Related]
4. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Poirel L, Naas T, Le Thomas I, Karim A, Bingen E, Nordmann P. Antimicrob Agents Chemother; 2001 Dec; 45(12):3355-61. PubMed ID: 11709308 [Abstract] [Full Text] [Related]
5. A novel ceftazidime-hydrolysing extended-spectrum beta-lactamase, CTX-M-54, with a single amino acid substitution at position 167 in the omega loop. Bae IK, Lee BH, Hwang HY, Jeong SH, Hong SG, Chang CL, Kwak HS, Kim HJ, Youn H. J Antimicrob Chemother; 2006 Aug; 58(2):315-9. PubMed ID: 16785225 [Abstract] [Full Text] [Related]
6. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. Stürenburg E, Kühn A, Mack D, Laufs R. J Antimicrob Chemother; 2004 Aug; 54(2):406-9. PubMed ID: 15201232 [Abstract] [Full Text] [Related]
11. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160 [Abstract] [Full Text] [Related]
12. Unexpected enzyme TEM-126: role of mutation Asp179Glu. Delmas J, Robin F, Bittar F, Chanal C, Bonnet R. Antimicrob Agents Chemother; 2005 Oct; 49(10):4280-7. PubMed ID: 16189109 [Abstract] [Full Text] [Related]
13. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study]. Gür D, Gülay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, Eraç B, Gültekin M, Oğünç D, Söyletir G, Unal N, Uysal S. Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074 [Abstract] [Full Text] [Related]
14. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability. Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. J Mol Biol; 2005 Apr 29; 348(2):349-62. PubMed ID: 15811373 [Abstract] [Full Text] [Related]
16. Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y. Antimicrob Agents Chemother; 2009 Jan 29; 53(1):69-74. PubMed ID: 18955524 [Abstract] [Full Text] [Related]